WO2016208582A1 - Oral care composition for cancer patients - Google Patents

Abstract

The present invention relates to an oral care composition that prevents complications in the oral cavity and, at the same time, treats, ameliorates, relieves and/or alleviates inflammation (symptoms) in the oral cavity while improving QOL of cancer patients during treatment. More specifically, the present invention relates to an oral care composition for cancer patients, said composition comprising a tea extract, a thickening polysaccharide and a humectant.

Description

Oral care composition for cancer patients Reference to related applications

This patent application is accompanied by a claim of priority based on Japanese Patent Application No. 2015-125011 (filing date: June 22, 2015), which was a previously filed Japanese patent application. The entire disclosure of this earlier patent application is incorporated herein by reference.

Background of the Invention

TECHNICAL FIELD The present invention relates to an oral care composition for cancer patients.

BACKGROUND ART In Japan, one in two men and one in three women suffer from cancer during their lifetime. Cancer treatment varies depending on the organ affected by the cancer and the stage of the cancer, but there are mainly three types of surgery, radiation therapy and chemotherapy. In addition, endocrine therapy and immunotherapy for special tumors. Etc. are known. In the treatment of cancer, a plurality of treatment methods may be combined, for example, with a focus on surgical therapy, and chemotherapy or radiation therapy may be combined before and after surgery.

When cancer is affected, nausea, decreased appetite, anemia, bone marrow suppression, etc. are caused as the cancer progresses, and this is accompanied by infections in the oral cavity (dental infections, oral candidiasis, herpes, etc.) ) And oral mucositis. In addition, as a side effect of cancer treatment, adverse events (oral mucositis, oral infection, dry mouth, etc.) occur in the oral cavity in any of surgical treatment, radiation therapy, and chemotherapy. % Is known to develop oral mucositis. Therefore, not only in Japan but also in other countries around the world, we are working on the development of therapeutic agents and preventive agents for oral complications including oral mucositis in cancer patients (Non-patent Document 1).

However, the development of effective drugs for oral complications in cancer patients, especially oral mucositis, has not progressed sufficiently, leading to the administration of local anesthetics to oral mucositis that actually developed and oral mucositis. The present situation depends on coping therapy such as oral care combined with the administration of anti-inflammatory agents or the use of oral moisturizers and gargle.

Two types of oral moisturizers are used: moisturizers that contain antibacterial substances and moisturizers that do not contain antibacterial substances. These oral moisturizers are effective in preventing dry mouth and oral infections that occur at the same time as oral mucositis. On the other hand, when targeting cancer patients, the oral environment deteriorates and severe oral intima There is concern about the possibility of causing a flame.

In addition, in gout, the time for keeping the oral cavity clean is short, and effective oral care requires practice once every 2 to 3 hours. It is a thing to force. In recent years, focusing on the antibacterial action of catechins, it has been studied to prevent stomatitis in cancer patients by gargle using an aqueous catechin solution (Non-patent Document 2). However, in order to exert antibacterial and preventive effects using tea catechins, catechins having a higher concentration (1.5 mg / ml) than catechin concentrations (0.8 mg / ml) contained in normal tea beverages It is necessary to use an aqueous solution. Therefore, in the prevention of stomatitis by gargle using high concentration catechin aqueous solution, when actually garnishing, the taste stimulation such as bitter taste and astringency is too strong, and the taste is stimulated and accompanied by pain, etc. It is hard to say from the viewpoint of (Quality 好 ま し い of Life). Moreover, since it is difficult to actually gargle a patient with dysphagia, gargle using an aqueous catechin solution cannot be applied. Furthermore, since the tea catechin aqueous solution can be easily oxidized by increasing the dissolved oxygen concentration, it must be prepared at the time of use.

On the other hand, the present inventors have shown antibacterial activity to at least one of periodontal disease bacteria, caries-causing bacteria, and opportunistic infection-causing bacteria, but do not show antibacterial activity to oral resident bacteria, An oral care composition containing catechin and gelled with xanthan gum, which is a moisturizing agent, has been developed (Patent Document 1). However, this composition for oral care is used for the adjustment of the normal oral flora, and in Patent Document 1, it is used for oral complications in cancer patients, particularly oral mucositis in cancer treated patients. There is no disclosure about.

International Publication 2013/100089

Thus, as far as the inventors know, it is possible to prevent the development of oral complications while improving QOL in cancer patients, and to treat, improve, reduce and / or alleviate inflammation (symptoms) in the oral cavity. No known oral care composition has been known.

The present inventors have now used oral care compositions comprising tea extract, thickening polysaccharides and humectants to reproduce oral mucositis in the oral cavity of cancer patients. In model mice, the present inventors succeeded in suppressing ulcer onset during ulcer onset and promoting ulcer repair during ulcer repair. That is, it has been found that by using the composition for oral care of the present invention, the onset of oral complications can be prevented and inflammation of oral complications can be reduced. The present invention is based on these findings.

That is, the present invention is for oral care for preventing the onset of oral complications and treating, improving, reducing and / or alleviating oral inflammation (symptoms) while improving QOL in cancer treated patients. It is an object to provide a composition.

According to the present invention, the following inventions are provided.
(1) A composition for oral care for cancer patients, comprising a tea extract, a thickening polysaccharide and a humectant.
(2) In the above (1) for preventing, treating, ameliorating, reducing and / or alleviating oral complications of cancer patients who receive at least one treatment selected from surgical therapy, radiation therapy and chemotherapy The composition for oral care as described.
(3) The composition for oral care according to (2) above, wherein the oral complication is caused by radiation therapy or chemotherapy.
(4) The composition for oral care according to (2) or (3) above, wherein the oral complication is oral mucositis.
(5) The oral cavity according to the above (3) or (4), which is administered so that the concentration of tea catechin in the oral cavity is 1 to 100 μg / cm ² per unit time before radiation therapy or chemotherapy is performed. Care composition.
(6) The oral care composition according to any one of (1) to (5) above, wherein the concentration of catechin contained in the tea extract relative to the oral care composition is 0.05 to 1% by weight.
(7) The composition for oral care according to any one of (1) to (6) above, wherein the thickening polysaccharide is xanthan gum.
(8) The composition for oral care according to any one of (1) to (7) above, wherein the humectant is glycerin or propylene glycol.
(9) The oral care composition according to any one of (1) to (8) above, which is in the form of a gel, liquid, cream or ointment.

The composition for oral care of the present invention can maintain the tea catechin concentration in the oral cavity for a long time, can prevent the onset of oral complications, and treat inflammation (symptoms) of oral complications, Can be improved, reduced and / or alleviated. Moreover, since the composition for oral care of this invention contains a thickening polysaccharide and can be ingested (administered) locally, it suppresses the irritation | stimulation to the taste by catechin at the time of ingestion (administration). It can also be retained in the ingestion (administration) part for a long time. Therefore, the oral care composition of the present invention is advantageous in that it can improve QOL in cancer treated patients while reducing the actual number of times of administration (administration).

3 shows the transition of the average ulcer area in the ulcer onset period (6th to 11th days after the first anticancer drug administration) in the oral mucositis model mouse. Mean ulcers in the oral mucositis model mice in the onset of ulcers (days 6 to 11 after administration of the first anticancer agent) and ulcer repair periods (days 12 to 16 after administration of the first anticancer agent) The change of the area is shown. It is the graph which showed the ulcer state (degree of ulcer) of an ulcer onset period, an ulcer repair period, and the whole period by the product of an ulcer area and the measurement days, ie, AUC (area under a curve). It is the graph which showed the result of the sustained release test. (A) Catechin concentration (mg / L) released at each time (every 2 hours). (B) Catechin concentration released over time (mg / L).

Detailed Description of the Invention

Oral Care Composition The oral care composition of the present invention comprises a tea extract, a thickening polysaccharide and a humectant as active ingredients, and is used (administered) to cancer patients. The composition for oral care of the present invention is a selective antibacterial action capable of adjusting the normal microbial flora, oxidative stress (reactive oxygen) generated in the oral mucosa of cancer patients given by free radicals generated by chemotherapy or radiotherapy Therefore, oral complications of cancer patients can be efficiently prevented, treated, improved, reduced and / or alleviated.

In the present invention, “cancer patient” means a patient suffering from cancer. In the present invention, “cancer” includes cancer (carcinoma), sarcoma, leukemia / malignant lymphoma, and the like, which are also called malignant tumors or malignant neoplasms.

In the present invention, the “cancer patient” is preferably a cancer patient who receives treatment for cancer, more preferably at least one treatment selected from surgical therapy, radiation therapy and chemotherapy, A cancer patient, more preferably a cancer patient who receives at least one treatment selected from radiation therapy and chemotherapy.

“Surgery” refers to a surgical operation for cancer occurring in the upper gastrointestinal tract and respiratory organs as well as in the oral cavity, head and neck region. In general, patients who have undergone head and neck surgery, including the oral cavity, have defects in tissues related to mastication and swallowing functions, and those who have undergone upper gastrointestinal and respiratory surgery are fed parentally. Ingestion tends to cause infections in the oral cavity and oral mucositis.

"Radiotherapy" refers to local therapy that irradiates cancer cells with radiation. Radiation therapy affects not only cancer cells but also normal cells around them. Generally, in radiation therapy, when the oral cavity, head and neck region enters the radiation field, an adverse reaction (oral adverse event) always occurs in the oral cavity, and mainly oral mucositis due to active oxygen occurs and is irreversible. Severe dry mouth due to atrophy of the salivary glands.

In radiation therapy for head and neck cancer, for example, about 2 Gy (gray) is applied 5 times a week for 6 to 7 weeks to achieve an irradiation dose of 60 to 70 Gy, which is used in combination with surgery and chemotherapy. Often. When the irradiation dose is 10 Gy or more (after the first week), saliva thickening is often observed, and when the irradiation dose is 20 Gy or more (after the second week), the oral mucosa is reddish, and some Mucous membranes have peeling ulcers, and taste changes are often seen. When the irradiation dose is 30 Gy or more (after 3 weeks), ulcer formation is promoted and the amount of saliva secretion decreases. When the irradiation dose is 50 Gy or more (after the 5th week), the formation of ulcers further progresses and the intake of food is often difficult, and when the irradiation dose is 60 Gy or more (after the 6th week) It becomes a symptom of severe oral mucositis and often reaches the peak of oral mucositis and dry mouth at the end of irradiation. Symptoms of oral mucositis often go away in 1 to 2 months.

“Chemotherapy” refers to the administration of anticancer drugs to suppress cancer cell growth and destroy cancer cells. Examples of anticancer agents include antimetabolites, alkylating agents, anticancer antibiotics, microtubule agonists, platinum preparations (platinum preparations), topoisomerase inhibitors, taxane preparations, and molecular target drugs. It is done. As anticancer agents with high incidence of oral mucositis, antimetabolites such as 5-FU, methotrexate, TS-1, capecitabine, cytarabine, gemcitabine, hydroxyurea, alkylating agents such as busulfan, melphalan, For cyclophosphamide, anticancer antibiotics, for example, bleomycin, daunorubicin, doxorubicin, actinomycin D, microtubule agonists, platinum preparations (platinum preparations), for example cisplatin, carboplatin, topoisomerase inhibitors, for example irinotecan Examples of etoposide and taxane preparations include paclitaxel and docetaxel, and examples of molecular targeted drugs include everolimus and temsirolimus. In general, chemotherapy often reduces the function of not only cancer cells but also normal cells that are actively proliferating, especially bone marrow cells and other cell groups related to immunity. It is easy to produce. In addition, in chemotherapy, active oxygen is generated in the oral mucosa by an anticancer agent, and oral mucositis due to active oxygen is likely to occur.

The oral care composition of the present invention is preferably used to prevent, treat, ameliorate, reduce and / or alleviate oral complications in cancer patients who are treated for cancer, more preferably surgery. Used to prevent, treat, ameliorate, reduce and / or alleviate oral complications in cancer patients who receive at least one treatment selected from therapy, radiation therapy and chemotherapy, more preferably radiation therapy and It is used to prevent, treat, ameliorate, reduce and / or alleviate oral complications in cancer patients who receive at least one treatment selected from chemotherapy. Here, prevention means preventing the onset of oral complications and mildly suppressing the onset of oral complications. Specifically, it acts on the pathogenesis of oral complications in advance. Prevent the onset of such diseases, acquire the function of oral complications more than normal or remission in advance, and reduce the physiological damage of the lesions caused after the onset of the disease, etc. means.

In the oral care composition of the present invention, oral complications such as oral mucositis and oral cavity such as oral mucositis, dental caries, periodontal disease and candidiasis are prevented, treated, improved, reduced and / or alleviated. Infectious diseases, dry mouth due to salivary gland dysfunction, and the like, including those with bleeding and pain, preferably oral mucositis. In the present invention, the “oral complication” may be one type of symptom alone or a combination of two or more types of symptoms among these oral complications. In the present invention, “oral complications” are preferably those caused as side effects by radiation therapy or chemotherapy, more preferably those caused by chemotherapy, more preferably antimetabolite administration therapy, particularly Preferably, it is caused by 5-FU administration therapy.

“Oral mucositis” is also called mucositis or stomatitis, and forms symptoms such as redness and ulceration in the mucous membrane and is accompanied by intense pain. Here, oral mucositis is 40-70% of cancer patients who receive chemotherapy, 80% of patients with hematopoietic stem cell transplantation who receive large doses of anticancer drugs and whole body irradiation, radiation glands in the head and neck It is said to occur in 100% of cancer patients receiving therapy. In oral mucositis, since it is difficult to take a meal orally with pain, the state of the whole body is weakened, resulting in serious side effects that affect the willingness to continue treatment and the willingness to fight. In oral mucositis, active oxygen is generated in the oropharyngeal mucosa due to radiation, an anticancer agent, etc., and active oxygen stays in the oral mucosa for a long time to cause oral mucositis. Generally, in chemotherapy, oral mucositis develops 7 to 10 days after the start of administration of an anticancer drug. Often subsides in about 2 weeks after onset, but may continue for more than a month. In radiation therapy, when the irradiation dose is 20 Gy or more, the oral mucosa is reddish and some mucous membranes are peeled and ulcers are observed. When the irradiation dose is 30 Gy or more, the formation of ulcers is promoted and the irradiation dose is 60 Gy or more. Then, it becomes a symptom of severe oral mucositis and often reaches the peak of oral mucositis at the end of irradiation. In many cases, symptoms subside after 1 to 2 months from the end of irradiation.

“Dry mouth” is also called xerostomia (dry mouth), and refers to symptoms accompanied by abnormal dryness in the oral cavity due to a decrease in salivary secretion. Here, the decrease in the amount of saliva secretion causes a decrease in the self-cleaning action in the oral cavity, the wet state in the oral cavity, the mucosal protective action in the oral cavity, and the like, which directly and indirectly cause other oral complications. And salivary gland atrophy is caused by radiation therapy of cancer patients who receive radiation therapy in the head and neck, causing irreversible and difficult to dry mouth, resulting in infections in the oral cavity and oral cavity Susceptible to mucositis.

“Oral infection” refers to an infection caused by pathogenic microorganisms in the oral cavity. Here, as pathogenic microorganisms (causing bacteria), for example, caries-causing bacteria (Actinomyces naeslundii and Streptococcus mutans 少 な く と も), periodontal disease-causing bacteria (Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans, Prevotella intermedia and Fusobacterium nucleatum), Candida 菌 albicans, methicillin-resistant Staphylococcus aureus (MRSA), and other causative agents of opportunistic infections. Oral infections are likely to occur if the balance of the normal bacterial flora in the oral cavity, such as a decrease in immunity, is lost.

The “tea extract” typically refers to a mixture extracted from tea and contains tea polyphenols, and preferably contains catechins at a high concentration. In the present invention, the “tea extract” may be a catechin obtained by purifying a specific polyphenol such as catechin, a synthesized catechin, or a commercially available tea extract. Here, examples of the tea extract include Sanphenon BG-5 (Taiyo Kagaku), Sunphenon BG-3 (Taiyo Kagaku), and Camellia Extract 30S (Taiyo Kagaku).

“Catechin” includes epi-forms, non-epi-forms, hydroxy forms, gallate esters, and the like. Here, as catechin, for example, epicatechin (EC), epigallocatechin (EGC), epicatechin gallate (ECg), epigallocatechin gallate (EGCg), catechin (C), gallocatechin (GC), catechin gallate (Cg) , Gallocatechin (GC) and the like. In the present invention, “catechin” may be a single kind of these catechins or a combination of two or more kinds (mixtures), but is easily available. And, since it has a good flavor, a mixture of catechins is preferable.

In the composition for oral care of the present invention, the content of the tea extract is not particularly limited as long as the bitterness derived from polyphenols such as catechin is less affected and the selective antibacterial effect and active oxygen removal effect are exhibited. Here, if the content of catechin is 0.05% by weight or more, for example, the selective antibacterial effect and the active oxygen removal effect are sufficiently expected, preferably 0.05 to 1% by weight, more preferably 0.05 to 0.8% by weight, more preferably 0.05 to 0.6% by weight, further preferably 0.05 to 0.5% by weight, particularly preferably 0.1 to 0.4% by weight. .

“Selective antibacterial effect” refers to an effective amount of catechin, specifically, caries-causing bacteria (at least one of Actinomyces naeslundii and Streptococcus mutans 、), periodontal disease-causing bacteria (Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans, At least one of the causative bacteria of opportunistic infections such as Prevotella intermedia and Fusobacterium nucleatum, Candida albicans, and methicillin-resistant Staphylococcus aureus (MRSA), but has high antibacterial activity It means that it does not affect the normal flora. Therefore, if the composition for oral care of the present invention is used, the hygiene condition in the oral cavity can always be adjusted satisfactorily without breaking the balance of the normal bacterial flora in the oral cavity.

“Removing effect of active oxygen” means removing or suppressing oxidative stress (reactive oxygen) generated in the oral mucosa of cancer patients given by anti-cancer drugs or free radicals generated by radiation associated with chemotherapy or radiation therapy Means that.

The “thickening polysaccharide” is not particularly limited as long as it can be administered into the oral cavity, in particular, can be locally administered to the inflamed area, and can exhibit retention and sustained release in the oral cavity. Here, as the thickening polysaccharide, for example, xanthan gum, agar, agarose, agaropectin, amylopectin, isolikenan, laminaran, lichenan, glucan, levan, fructan, galactan, mannan, xylan, arabinan, pentozan, alginic acid, pectic acid, fucoidan, pectin , Locust bean gum, guar gum, tara gum, gum arabic and the like. In the present invention, the “thickening polysaccharide” may be a single type of these thickening polysaccharides or a combination (mixture) of two or more types. Further, since it has a moisturizing action, xanthan gum and guar gum are preferable, and further, oxidation of tea catechin can be suppressed, and xanthan gum is more preferable.

In the oral care composition of the present invention, the content of the thickening polysaccharide is not particularly limited as long as the effects of retention and sustained release such as catechin are exhibited in the oral cavity. Here, when the xanthan gum content is, for example, 1% by weight or more, the effect of retention and sustained release of polyphenols such as catechin in the oral cavity is sufficiently expected, preferably 1 to 8% by weight, more preferably Is 2 to 7% by weight, more preferably 2.5 to 5.5% by weight. In addition, you may use another thickening polysaccharide with content equivalent to this.

The “humectant” is not particularly limited as long as it is a substance having a moisturizing action. Here, examples of the humectant include carrageenan, hyaluronic acid, glycerin, propylene glycol, polyethylene glycol, sorbit liquid, and carboxymethyl cellulose. In the present invention, the “humectant” may be a single type of these humectants or a combination (mixture) of two or more types. A mixture of glycerin and propylene glycol is preferable because it effectively improves and maintains the wet state.

In the composition for oral care of the present invention, the content of the moisturizing agent is not particularly limited as long as the effect of retention of active ingredients such as catechin, sustained release, and moisturizing effect is exhibited in the oral cavity. Here, if it is a mixture of glycerin and propylene glycol, if the content of glycerin is, for example, 5% by weight or more, in the oral cavity, the retention of active ingredients such as catechin, sustained release and moisturizing effects are It is sufficiently expected, preferably 5 to 40% by weight, more preferably 10 to 30% by weight, still more preferably 15 to 25% by weight. Of these, the effects of retention, sustained release and moisture retention of an active ingredient such as catechin are sufficiently expected, preferably 1 to 25% by weight, more preferably 2.5 to 20% by weight, still more preferably 5 to 5%. 15% by weight. In addition, you may use another moisturizing agent with content equivalent to this.

According to a preferred embodiment of the present invention, the oral care composition of the present invention comprises catechin, xanthan gum, glycerin and propylene glycol, and the content of catechin is 0.05% by weight or more, preferably 0.05. To 1% by weight, more preferably 0.05 to 0.8% by weight, still more preferably 0.05 to 0.6% by weight, still more preferably 0.05 to 0.5% by weight, particularly preferably 0.1 The content of xanthan gum is 1% by weight or more, preferably 1 to 8% by weight, more preferably 2 to 7% by weight, still more preferably 2.5 to 5.5% by weight. The glycerin content is, for example, 5% by weight or more, preferably 5 to 40% by weight, more preferably 10 to 30% by weight, still more preferably 15 to 25% by weight. The content of the glycol, 1% by weight or more, preferably 1 to 25 wt%, more preferably from 2.5 to 20 wt%, more preferably 5 to 15 wt%.

According to a more preferred embodiment of the present invention, the oral care composition of the present invention comprises catechin, xanthan gum and propylene glycol, the catechin content is 0.05 to 1 wt%, and the xanthan gum content is 1 to 8% by weight, glycerin content is 5 to 40% by weight, and propylene glycol content is 1 to 25% by weight. According to a further preferred embodiment of the present invention, the oral care composition of the present invention comprises catechin, xanthan gum and propylene glycol, the catechin content is 0.05 to 1% by weight, and the xanthan gum content is 2%. The glycerin content is 15 to 25% by weight, and the propylene glycol content is 5 to 15% by weight.

The oral care composition of the present invention may preferably contain an antioxidant and a preservative in addition to the above active ingredients from the viewpoint of long-term storage.

The “antioxidant” is not particularly limited as long as it is a substance having an antioxidant action. Here, examples of the antioxidant include erythorbic acid, ascorbic acid, tocopheric acid, tocopherol acetate, cyclodextrin, and salts or derivatives thereof. In the present invention, the “antioxidant” may be a single type of these antioxidants or a combination (mixture) of two or more types. From the viewpoint of preservation, erythorbic acid and / or sodium erythorbate is preferably a single substance or a mixture thereof. In the present invention, as the “antioxidant”, those for usual food addition can be used as they are.

In the composition for oral care of the present invention, the content of the antioxidant is not particularly limited as long as the antioxidant effect in long-term storage is exhibited. Here, if the content of erythorbic acid and / or sodium erythorbate alone or as a mixture is, for example, 0.01% by weight or more, the antioxidant effect in long-term storage is sufficiently expected, preferably 0.01 to It is 1.0% by weight, more preferably 0.02 to 0.5% by weight, still more preferably 0.05 to 0.1% by weight. In addition, you may use another antioxidant by content corresponding to this.

The “preservative” is not particularly limited as long as it is a substance having an antiseptic action. Here, examples of the preservative include cetylpyridinium chloride, ethyl paraoxybenzoate, methyl paraoxybenzoate, propyl paraoxybenzoate, phenoxyethanol, isopropylmethylphenol, alkyldiaminoethylglycine hydrochloride, sodium benzoate, and potassium sorbate. . In the present invention, the “preservative” may be a single kind of these preservatives, or may be a combination of two or more kinds (mixtures). From the viewpoint, it is preferably a single or a mixture of methyl paraoxybenzoate, propyl paraoxybenzoate, phenoxyethanol, isopropylmethylphenol and / or alkyldiaminoethylglycine hydrochloride. In the present invention, as the “preservative”, a conventional food additive can be used as it is.

In the oral care composition of the present invention, the content of the preservative is not particularly limited as long as the antiseptic effect and the miscellaneous taste suppressing effect during long-term storage are exhibited. Here, when the content of methyl paraoxybenzoate and / or propyl paraoxybenzoate alone or as a mixture is, for example, 0.01% by weight or more, the antiseptic effect and the miscellaneous taste suppressing effect in long-term storage are sufficiently expected. The content is preferably 0.01 to 1.0% by weight, more preferably 0.04 to 0.5% by weight, and still more preferably 0.05 to 0.1% by weight. In addition, when the content of phenoxyethanol is, for example, 0.1% by weight or more, the antiseptic effect and the miscellaneous taste suppressing effect in long-term storage are sufficiently expected, preferably 0.1 to 1.5% by weight, more preferably It is 0.3 to 1.3% by weight, more preferably 0.5 to 1.0% by weight. Further, when the content of isopropylmethylphenol is, for example, 0.0025% by weight or more, the antiseptic effect and the miscellaneous taste suppressing effect in long-term storage are sufficiently expected, preferably 0.0025 to 0.1% by weight, The amount is preferably 0.005 to 0.09% by weight, more preferably 0.01 to 0.08% by weight. Further, when the content of alkyldiaminoethylglycine hydrochloride is, for example, 0.03% by weight or more, the antiseptic effect and the miscellaneous taste suppressing effect in long-term storage are sufficiently expected, and preferably 0.03 to 0.8 % By weight, more preferably 0.05 to 0.4% by weight, still more preferably 0.1 to 0.2% by weight.

In addition to the above active ingredients, antioxidants, and preservatives, the oral care composition of the present invention is a general oral cavity within the range that does not impair the effects of the present invention and the retention and sustained release properties of the present invention. It may contain general additives used in care compositions and foods. Here, if the content of xylitol is, for example, 0.02% by weight or more, the improvement of the effect of the present invention is sufficiently expected, preferably 0.02 to 4% by weight, more preferably 0.3 to 4% by weight. It is 3% by weight, more preferably 0.5 to 2% by weight. In addition, in the composition for oral care of this invention, the manufacturing method and manufacturing process of a general composition for oral care can be applied.

The oral care composition of the present invention is preferably a tea extract (tea catechin), a thickening polysaccharide, xanthan gum, humectants, glycerin and propylene glycol, antioxidants, sodium erythorbate, preservatives , Ethyl paraben and propyl paraben, xylitol, and a fragrance.

The oral care composition of the present invention has a predetermined viscosity, and the viscosity measured with a B-type viscometer (measurement temperature: 20 to 25 ° C., shear rate corresponding to a rotation speed of 12 rpm) is, for example, 5 to If it is 1,000 Pa · s, it is easy to adjust the retention and sustained release of an active ingredient such as catechin in the oral cavity, and therefore, preferably 10 to 500 Pa · s, more preferably 20 to 400 Pa · s, The pressure is preferably 30 to 300 Pa · s. Further, the composition for oral care of the present invention has a predetermined light transmittance, and preferably has a light transmittance of a wavelength of 800 nm, for example, if it is 2% or more, the appearance is good. It is 2 to 95%, more preferably 5 to 90%, still more preferably 10 to 80%.

The oral care composition of the present invention has a predetermined form, and as a specific form, gel, liquid, foam, cream, ointment, etc. can be applied, and saliva is used in the oral cavity, A film, a tablet, or the like may be applied as long as it is dissolved in water or the like and has a predetermined viscosity. Here, the oral care composition of the present invention preferably has good handling properties such as actual administration (ingestion) and application, and retention and release of active ingredients such as catechin in the oral cavity. Since it is easy to adjust the properties, it is preferably a gel, and since it can be easily used with one hand, it is more preferably a sprayable gel. In addition, if it is a gel, viscosity (viscosity) can satisfy | fill the favorable range. Moreover, the composition for oral care of this invention may distribute | circulate in the form which impregnated and apply | coated to sponge, a toothbrush, a cotton swab, or a sheet | seat beforehand, and was individually packaged in the case of a gel etc.

The composition for oral care of the present invention can be used as a pharmaceutical, a quasi-drug, or a cosmetic, preferably an oral cosmetic, as it is or in combination with other components.

According to one aspect of the present invention, the oral care composition of the present invention is labeled with an indication that it is effective in treating oral complications in cancer patients, preferably cancer patients. Indices may be attached to indicate that they are effective in preventing, treating, improving, reducing and / or alleviating oral complications. And according to another aspect of the present invention, preferably the one with indication indicating that it is effective in the treatment of oral complications in a cancer patient, preferably receiving cancer treatment, preferably In addition, a sign indicating that the treatment is effective in preventing, treating, ameliorating, reducing and / or alleviating oral complications in a cancer patient may be given. In addition, according to another aspect of the present invention, more preferably, it is effective in the treatment of oral complications in cancer patients who receive at least one treatment selected from surgical therapy, radiation therapy, and chemotherapy. Prevention, treatment, amelioration, and / or prevention of oral complications in cancer patients who have at least one treatment selected from surgical therapy, radiation therapy, or chemotherapy, with an indication that it is present Or the display which shows that it is effective in relaxation may be attached | subjected. Here, the indication of the present invention is not particularly limited as long as it is given in relation to the composition for oral care, and for example, the oral care is applied to a container, packaging material or package insert containing the composition for oral care. It may be provided with a display / advertisement etc. for which the composition is effective. In addition, as long as it is inactive with the component of the composition for oral care as a container and packaging material of this invention, it will not specifically limit, For example, you may apply glass, a plastics, or a metal. In addition, the display of the present invention is a display in which the oral care composition is effective for storage media such as flyers, brochures, pops, catalogs, posters, posters, books, DVDs, advertisements on electronic bulletin boards, the Internet, etc. -An advertisement etc. may be attached.

According to one aspect of the present invention, the oral care composition of the present invention is a containerized oral care composition. The container-packed oral care composition of the present invention is a form in which an oral care composition comprising a tea extract, a thickening polysaccharide and a humectant is applied as a gel, liquid, foam, cream, ointment, etc. For example, it can be obtained by filling the oral care composition of the present invention into a container. The container used in the container-packed oral care composition of the present invention is not particularly limited, and for example, glass, plastic, PET bottle, paper pack, or metal (for example, aluminum, steel) may be used. The container-packed oral care composition is preferable because it does not come into contact with air and thus has an antioxidant function. According to a more preferred embodiment of the present invention, the container-packed oral care composition of the present invention is 1 to 120 times, more preferably 1 to 90 times, still more preferably 1 to 80 times, still more preferably 1 to 60 times. Specifically, in the case of a gel, it is a type of 1 to 100 ml, more preferably 1 to 90 ml, still more preferably 1 to 80 ml, still more preferably 1 to 60 ml. The container-packed oral care composition of the present invention may be a single-use individual package.

According to one aspect of the present invention, the oral care composition of the present invention comprises oral complications of cancer patients, preferably comprising tea extract, thickening polysaccharide and humectant as active ingredients. It may be a composition for preventing, treating, improving, reducing and / or alleviating oral mucositis. Preferably, the composition of the present invention prevents, treats, ameliorates or reduces oral complications in cancer patients, preferably oral mucositis, receiving at least one treatment selected from surgical therapy, radiation therapy and chemotherapy. And / or a palliative composition, and more preferably, prevention, treatment, amelioration of oral complications in cancer patients, preferably oral mucositis, receiving at least one treatment selected from radiation therapy and chemotherapy, A mitigating and / or mitigating composition.

According to a preferred embodiment of the present invention, the composition for oral care of the present invention comprises, as an active ingredient, surgical treatment, radiation therapy and cancer therapy comprising a tea extract, a thickening polysaccharide and a humectant. Composition for preventing, treating, ameliorating, reducing and / or alleviating oral complications as a side effect caused by at least one treatment selected from chemotherapy, preferably oral mucositis, more preferably radiation of cancer patients A composition for preventing, treating, ameliorating, reducing and / or alleviating oral complications as a side effect caused by at least one treatment selected from therapy and chemotherapy, preferably oral mucositis, more preferably for cancer patients Prevention of oral complications as a side effect caused by chemotherapy (preferably antimetabolite administration, more preferably 5-FU administration), preferably oral mucositis, Care, improvement, and alleviation and / or alleviating composition.

Method for treating oral complications When the composition for oral care of the present invention is used, the selective antibacterial action of the composition, the action of removing oxidative stress generated in the oral mucosa of cancer patients, and the moisturizing action The patient's oral complications can be effectively prevented, treated, ameliorated, reduced and / or alleviated. And, by using the composition for oral care of the present invention, preferably, the onset of oral complications in cancer patients can be efficiently prevented, and at the same time, oral complications can be treated, improved, reduced and / or Can be relaxed. Here, when the oral complication of the cancer patient is intraoral inflammation such as oral mucositis, the oral care composition of the present invention is used to treat, ameliorate, reduce and / or reduce the oral complication of the cancer patient. At the same time, the inflammatory condition can be suppressed.

According to another aspect of the present invention, there is provided a method for treating oral complications comprising administering the oral care composition of the present invention to a cancer patient, preventing oral complications, Treatment, amelioration, alleviation and / or alleviation methods are provided. And according to another aspect of the present invention, there is provided a method for treating oral complications, preferably comprising administering to a cancer patient, receiving treatment for cancer, Methods of prevention, treatment, amelioration, reduction and / or alleviation are provided. In addition, according to another aspect of the present invention, more preferably, the oral cavity comprising administering to a cancer patient who receives at least one treatment selected from surgical therapy, radiation therapy, and chemotherapy. Methods for treating complications are provided, and methods for preventing, treating, ameliorating, reducing and / or alleviating oral complications are provided.

In the method for treating oral complications of the present invention, since the preventive effect of oral complications can be improved, preferably, the oral care composition of the present invention is applied to cancer patients before cancer treatment is performed. A method of administering to a cancer patient, more preferably a method of administering the oral care composition of the present invention to a cancer patient before cancer chemotherapy or radiation therapy is performed on the cancer patient. It is. The method for treating oral complications according to the present invention preferably excludes medical practice for humans. Here, the medical practice for humans means an act of taking (administering) pharmaceuticals to humans, which requires prescription by a doctor or the like.

The treatment method of the present invention can be performed according to the contents described in the present specification for the oral care composition of the present invention.

In the oral care composition of the present invention, a wide range of administration (ingestion) methods such as oral administration such as eating and drinking, topical administration such as application to the oral cavity, and toothpaste, depending on the use state and use scene. Can be applied. Here, when the oral care composition of the present invention is orally administered by eating or drinking, as an effective dose for preventing, treating, improving, reducing and / or alleviating oral complications of cancer patients, Based on catechin, it is preferably equivalent to 10 to 100 mg. In addition, when the oral care composition of the present invention is locally administered by application to the oral cavity or the like, the administration is effective for preventing, treating, improving, reducing and / or alleviating oral complications in cancer patients. Based on catechin as the amount, the catechin concentration in the oral cavity is preferably 1 to 100 μg / cm ² per unit time (1 hour). When the oral care composition of the present invention is a commercially available aurora coat, catechin is used as an effective dose for preventing, treating, improving, reducing and / or alleviating oral complications in cancer patients. Based on the standard, from the viewpoint of sustained release of catechin, for example, 1 g is used as a single dose, at least twice a day, preferably at least 3 times a day, more preferably at least 4 times, and even more preferably 1 The frequency is 6 times or more per day (see Example 2 in the Examples).

The oral care composition of the present invention applies a wide range of administration (intake) periods such as when feeling dry, feeling pain, after normal meals or before going to bed, depending on the state of use and scene of use. be able to.

According to another aspect of the present invention, there is provided the use of the oral care composition of the present invention for the treatment of oral complications in cancer patients, and the prevention and treatment of oral complications in cancer patients. There is provided the use of the oral care composition of the present invention for improvement, reduction and / or alleviation. And according to another aspect of the present invention there is provided the use of the oral care composition of the present invention for the treatment of oral complications in cancer patients, preferably receiving treatment for cancer. Provided is the use of the oral care composition of the present invention for the prevention, treatment, amelioration, reduction and / or alleviation of oral complications in cancer patients who are treated for cancer. Also, according to another aspect of the present invention, more preferably, for the treatment of oral complications in cancer patients who receive at least one treatment selected from surgical therapy, radiation therapy, chemotherapy. Prevention, treatment, amelioration, and / or reduction of oral complications in cancer patients, provided that the use of the oral care composition of the present invention is provided and receives at least one treatment selected from surgical therapy, radiation therapy, chemotherapy. Or use of the oral care composition of the present invention for relief is provided.

According to another aspect of the present invention, there is provided the use of the oral care composition of the present invention in the manufacture of a medicament for the treatment of oral complications in cancer patients, and oral complications in cancer patients. There is provided the use of the oral care composition of the present invention in the manufacture of a medicament for the prevention, treatment, amelioration, alleviation and / or alleviation. And according to another aspect of the present invention, preferably the oral care composition of the present invention in the manufacture of a medicament for the treatment of oral complications in a cancer patient who is treated for cancer Use of the oral care composition of the present invention in the manufacture of a medicament for the prevention, treatment, amelioration, reduction and / or alleviation of oral complications in a cancer patient Provided. Moreover, according to another aspect of the present invention, more preferably, an agent for the treatment of oral complications in a cancer patient that receives at least one treatment selected from surgical therapy, radiation therapy, and chemotherapy The use of the oral care composition of the present invention in the manufacture of an oral complication prevents or treats or improves oral complications in cancer patients who receive at least one treatment selected from surgical therapy, radiation therapy, and chemotherapy There is provided the use of the oral care composition of the present invention in the manufacture of a medicament for relief and / or alleviation.

According to another aspect of the present invention there is provided the use of the oral care composition of the present invention in the manufacture of a cosmetic product for the treatment of oral complications in cancer patients, and oral complications in cancer patients. There is provided the use of the oral care composition of the present invention in the manufacture of a cosmetic product for prevention, treatment, amelioration, alleviation and / or alleviation. And according to another aspect of the present invention, preferably the oral care composition of the present invention in the manufacture of a cosmetic product for the treatment of oral complications in a cancer patient who is treated for cancer. Use of the oral care composition of the present invention in the manufacture of a cosmetic product for the prevention, treatment, amelioration, reduction and / or alleviation of oral complications in a cancer patient Provided. Moreover, according to another aspect of the present invention, more preferably, a cosmetic for the treatment of oral complications in a cancer patient, receiving at least one treatment selected from surgical therapy, radiation therapy, and chemotherapy. The use of the oral care composition of the present invention in the manufacture of an oral complication prevents or treats or improves oral complications in cancer patients who receive at least one treatment selected from surgical therapy, radiation therapy, and chemotherapy There is provided the use of the oral care composition of the present invention in the manufacture of a cosmetic product for relief and / or relief.

According to another aspect of the present invention there is provided the use of tea extract, thickening polysaccharide and humectant in the manufacture of an oral care composition for the treatment of oral complications in cancer patients, There is provided the use of tea extract, thickening polysaccharides and humectants in the manufacture of an oral care composition for the prevention, treatment, amelioration, alleviation and / or alleviation of oral complications in cancer patients. And according to another aspect of the present invention, preferably a tea extract, an increase in the manufacture of an oral care composition for the treatment of oral complications in a cancer patient who is treated for cancer. In the manufacture of an oral care composition for the prevention, treatment, amelioration, alleviation and / or alleviation of oral complications in cancer patients provided with the use of mucopolysaccharides and humectants Use of tea extract, thickening polysaccharides and humectants is provided. Moreover, according to another aspect of the present invention, more preferably, the oral cavity for the treatment of oral complications in cancer patients that receives at least one treatment selected from surgical therapy, radiation therapy, and chemotherapy. Oral mergers in cancer patients who are provided with the use of tea extract, thickening polysaccharides and humectants in the manufacture of care compositions and receive at least one treatment selected from surgical therapy, radiation therapy, chemotherapy Use of tea extract, thickening polysaccharides and humectants in the manufacture of an oral care composition for prevention, treatment, amelioration, alleviation and / or alleviation of diseases is provided.

According to another aspect of the invention, there is provided the use of a tea extract, a thickening polysaccharide and a humectant in the manufacture of a medicament for the treatment of oral complications in a cancer patient. There is provided the use of tea extract, thickening polysaccharides and humectants in the manufacture of a medicament for the prevention, treatment, amelioration, reduction and / or alleviation of oral complications. And according to another aspect of the present invention, preferably a tea extract, a thickening polysaccharide and a pharmaceutical in the manufacture of a medicament for the treatment of oral complications in a cancer patient who is treated for cancer Tea extract, thickening polysaccharide in the manufacture of a medicament for the prevention, treatment, amelioration, mitigation and / or alleviation of oral complications in cancer patients who are provided with the use of humectants and who are treated for cancer And the use of humectants. Moreover, according to another aspect of the present invention, more preferably, an agent for the treatment of oral complications in a cancer patient that receives at least one treatment selected from surgical therapy, radiation therapy, and chemotherapy Prevention of oral complications in cancer patients, provided the use of tea extract, thickening polysaccharides and humectants in the manufacture of and receiving at least one treatment selected from surgical therapy, radiation therapy, chemotherapy, There is provided the use of tea extract, thickening polysaccharides and humectants in the manufacture of a medicament for treatment, amelioration, alleviation and / or alleviation.

According to another aspect of the invention, there is provided the use of a tea extract, a thickening polysaccharide and a humectant in the manufacture of a cosmetic for the treatment of oral complications in a cancer patient, in a cancer patient. There is provided the use of tea extracts, thickening polysaccharides and humectants in the manufacture of cosmetics for the prevention, treatment, amelioration, reduction and / or alleviation of oral complications. And according to another aspect of the present invention, preferably tea extract, thickening polysaccharide and in the manufacture of cosmetics for the treatment of oral complications in cancer patients who are treated for cancer Tea extract, thickening polysaccharide in the manufacture of cosmetics for the prevention, treatment, amelioration, reduction and / or alleviation of oral complications in cancer patients who are provided with the use of moisturizers and who are treated for cancer And the use of humectants. Moreover, according to another aspect of the present invention, more preferably, a cosmetic for the treatment of oral complications in a cancer patient, receiving at least one treatment selected from surgical therapy, radiation therapy, and chemotherapy. Prevention of oral complications in cancer patients, provided the use of tea extract, thickening polysaccharides and humectants in the manufacture of and receiving at least one treatment selected from surgical therapy, radiation therapy, chemotherapy, There is provided the use of tea extracts, thickening polysaccharides and humectants in the manufacture of cosmetics for treatment, improvement, reduction and / or alleviation.

The use of the present invention can be carried out in accordance with the contents described in the present specification for the oral care composition of the present invention.

The present invention will be described in detail by the following examples, but the present invention is not limited thereto.

Example 1: Evaluation test of anti-ulcer effect using oral mucositis model mouse After anticancer drug was administered to mice and the function of cell groups related to immunity such as bone marrow cells was reduced, acetic acid was submucous into oral mucosa Oral mucositis model mice were prepared by an experimental system that artificially develops ulcers and the antiulcer effects of various preparations were evaluated.

(1) Preparation of oral mucositis model mouse Fluorouracil (5-FU, Wako Pure Chemical Industries, Ltd.) was used as an anticancer agent in the abdominal cavity of ICR mice (10 weeks old, male) (Japan SLC). Each was administered at 50 mg / kg. Then, the first administration day of the anticancer agent was taken as day 0 of the study, and on the second and fourth days of the study, an additional anticancer agent (5-FU) was administered, for a total of three times. A total of 150 mg / kg of anticancer drugs was administered to prepare oral mucositis model mice. Such an oral mucositis model mouse is used as a model mouse that mimics stomatitis caused by the side effect of an anticancer agent as a model mouse that substitutes for a disease model mouse using radiation.

On the day after the third administration day of the anticancer drug (the fifth day of the study), in order to artificially develop an ulcer, 15 μL of an acetic acid solution (20%, 3.16 mol / L) was added to the oral cavity of the mouse. Submucosal administration.

(2) Evaluation of anti-ulcer effect of various preparations The anti-ulcer effect of various preparations was evaluated using the oral mucositis model mouse of (1) above. For various preparations, the composition for oral care of the present invention (Aurora Coat, Meiji Co.) and a commercially available moisturizer (Oral Balance, Nippon Darm Co., Ltd.) were used. Here, a commercially available moisturizing agent is generally used mainly in the United States and Japan for the purpose of dry mouth care, and this main moisturizing component is polymethacryl glycerin.

Oral sonde needle with glass syringe (capacity: 0.25 ml, needle diameter: 20G, diameter of blunt; 2.25 mm, length: 2.5 cm, curvilinear) (SouthPointe Surgical Supply, CoralsSprings, FL , USA Co., Ltd.), 30 mg each of the oral care composition of the present invention or a commercially available moisturizing agent in the oral mucosa of an oral mucositis model mouse under non-anaesthesia twice a day (at 10 o'clock and 18 o'clock) Administration). At this time, there were 6 mice in each group (oral mucositis model mice administered with various preparations). In addition, in order to evaluate the preventive effect of the onset of ulcers, application of various preparations was started 7 days before the first anticancer drug administration (day 7 of the study). Continued until day 16 after administration.

The ulcer area developed in the oral cavity of each group of mice was determined at predetermined intervals from the day after the administration day of the acetic acid solution (20%) (study day 6) (measurement date: tests 6, 8, and 11). , 13, 16). Here, under anesthesia with isoflurane inhalation anesthesia, the major axis and minor axis were measured with a ruler to determine the ulcer area. In addition, as a control, the ulcer area was also determined in mice not receiving various preparations (untreated group).

The average value (average ulcer area) of the ulcer area of each group and the untreated group was calculated, and the average ulcer area of each group and the untreated group was compared to evaluate the anti-ulcer effect. Specifically, in the ulcer onset period (days 6 to 11 of the study), the ulcer onset suppression effect (ulcer prevention effect) was evaluated, and in the ulcer repair stage (day 12 to 16 of the study) The effect of promoting (treatment effect of ulcer) was evaluated. Each result is shown in FIG. 1 and FIG.

As shown in FIG. 1, in the ulcer onset period, the average ulcer area of the administration group of the oral care composition of the present invention was smaller than the average ulcer area of the untreated group. That is, it was confirmed that the composition for oral care of the present invention has an effect of suppressing the onset of ulcer (preventive effect of ulcer). This is because, when the oral care composition of the present invention is applied to the oral cavity before administration of the anticancer agent, antibacterial effects such as oral bacteria on the oral mucosa are caused by the anti-bacterial active ingredient catechin. It is presumed that both functions of the removal effect of “active oxygen derived from cancer drugs” were exerted, and the onset of ulcer due to acetic acid was suppressed. On the other hand, in the ulcer onset period, the average ulcer area of the group administered with the commercial moisturizer was larger than the average ulcer area of the untreated group. That is, it was confirmed that the commercially available moisturizing agent has no ulcer onset suppression effect (ulcer prevention effect) and rather has an ulcer onset promotion effect. This is because when a commercially available moisturizer is applied to the oral cavity before the administration of the anticancer agent, the moisturizing component (humectant) causes oral bacteria on the oral mucosa and other "active oxygen derived from the anticancer agent" It is inferred that the retention action was exerted and promoted damage to the oral mucosa.

As shown in FIG. 2, in the ulcer repair period, the average ulcer area of the oral care composition administration group and the commercial moisturizing agent administration group of the present invention was smaller than that of the untreated group. That is, it was confirmed that the composition for oral care and the commercially available moisturizing agent of the present invention have an ulcer repair promoting effect (ulcer treatment effect).

Furthermore, the ulcer onset period, the ulcer repair period, and the ulcer state (the degree of ulcer) of all the combined periods are indicated by the product of the ulcer area and the number of measurement days, that is, AUC (area under the curve). The ulcer status in was evaluated. The result is shown in FIG.

As shown in FIG. 3, the AUC of the oral care composition administration group of the present invention was smaller in the ulcer onset period, the ulcer repair period, and the entire period than in the untreated group AUC. On the other hand, in the ulcer onset period, the AUC of the commercial moisturizer group was larger than the AUC of the untreated group, and the AUC of the commercial moisturizer group was smaller than the AUC of the untreated group in the ulcer repair period and the whole period. It was.

Example 2: Evaluation test of sustained release The sustained release of the oral care composition (Aurora Coat, Meiji Co., Ltd.) of the present invention was confirmed. Here, the sustained release property was evaluated by the following procedure. The oral care composition was filled in 3 ml each in a 12-well plate (Falcon), and then filled in 3 ml PBS (multilayer treatment). After collecting the whole amount of the supernatant (PBS) every 2 hours after the stratification treatment (2, 4, 6, 8, 10, 12 hours after the stratification treatment) and after collecting the whole amount of the supernatant, Then, 3 ml of fresh PBS was filled (layered treatment).

The supernatant of each time after the stratification treatment was diluted 10-fold with water, and then HPLC [instrument: CBM-20A, LC-30AD-2 (pump), SIL-30AC (autoinjector), CTO-20AC (Column oven), SPD-M20A (detector), Shimadzu Corporation] was used to measure the catechin concentration. The result is shown in FIG. In the measurement of the catechin concentration, epigallocatechin gallate (EGCg) (standard solution: 1, 2, 10 mg / L) was used as a standard. The HPLC analysis conditions are as follows.

As shown in FIG. 4, the catechin release concentration per unit time (1 hour) of the oral care composition of the present invention was 27.1 μg / cm ² / h on average in 2 hours after the multi-layer treatment. The catechin release concentration per unit time (1 hour) of the oral care composition of the present invention was 2.5 μg / cm ² / h on average in 12 hours (integration) after the multi-layer treatment. . Thus, in the composition for oral care of the present invention, even if the catechin is a small amount (low concentration), since the catechin is gradually released over a long period of time, the antibacterial effect is effectively exhibited, It is useful in that irritation and bitterness caused by catechin are suppressed, and it can be continued comfortably.

Claims (9)

1. Oral care composition for cancer patients, comprising tea extract, thickening polysaccharide and moisturizer.
2. The oral care according to claim 1, for preventing, treating, ameliorating, reducing and / or alleviating oral complications of cancer patients who receive at least one treatment selected from surgical therapy, radiation therapy and chemotherapy. Composition.
3. The composition for oral care according to claim 2, wherein the oral complication is caused by radiation therapy or chemotherapy.
4. The composition for oral care according to claim 2 or 3, wherein the oral complication is oral mucositis.
5. The composition for oral care according to claim 3 or 4, which is used so that the concentration of tea catechin in the oral cavity becomes 1 to 100 µg / cm ² per unit time before radiation therapy or chemotherapy is performed.
6. The oral care composition according to any one of claims 1 to 5, wherein the concentration of catechin contained in the tea extract relative to the oral care composition is 0.05 to 1% by weight.
7. The oral care composition according to any one of claims 1 to 6, wherein the thickening polysaccharide is xanthan gum.
8. The composition for oral care according to any one of claims 1 to 7, wherein the humectant is glycerin or propylene glycol.
9. The oral care composition according to any one of claims 1 to 8, which is in the form of a gel, liquid, cream or ointment.

Images